Beijing Tiantan Biological Products , Ltd. EBIT

The latest EBIT for 600161.SS is $1.3B as of June 2026. That compares with $2.3B in the prior-year period — down 44.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Beijing Tiantan Biological Products , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 600161.SS's EBIT moved from $2.3B to $1.3B — a 44.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Beijing Tiantan Biological Products , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 600161.SS currently prints $1.3B for EBIT, while the sector average sits near $110B. That is roughly 98.8% below the sector mean. Large gaps often invite a closer look at Beijing Tiantan Biological Products , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $1.3B for 600161.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 600161.SS's EBIT ($1.3B), review year-over-year change from $2.3B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.